Front Row Advisors’s Arbutus Biopharma ABUS Stock Holding History

Front Row Advisors’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$497K	Buy	110,500 +100,000	+952%	+$437K	0.17%	75
2025 Q4	$50.5K	Hold	10,500	–	–	0.02%	217
2025 Q3	$47.7K	Hold	10,500	–	–	0.02%	221
2025 Q2	$32.4K	Hold	10,500	–	–	0.01%	242
2025 Q1	$36.6K	Hold	10,500	–	–	0.01%	241
2024 Q4	$34.3K	Hold	10,500	–	–	0.01%	250
2024 Q3	$40.4K	Hold	10,500	–	–	0.01%	237
2024 Q2	$32.4K	Hold	10,500	–	–	0.01%	326
2024 Q1	$27.1K	Hold	10,500	–	–	0.01%	341
2023 Q4	$26.3K	Hold	10,500	–	–	0.01%	228
2023 Q3	$21.3K	Hold	10,500	–	–	0.01%	371
2023 Q2	$24K	Hold	10,500	–	–	0.01%	339
2023 Q1	$32K	Hold	10,500	–	–	0.02%	292
2022 Q4	$24K	Hold	10,500	–	–	0.01%	338
2022 Q3	$20K	Hold	10,500	–	–	0.01%	376
2022 Q2	$28K	Hold	10,500	–	–	0.01%	315
2022 Q1	$31K	Buy	+10,500	New	+$32.1K	0.01%	324

Other funds holding ABUS

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

WCM

Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Front Row Advisors's ABUS Position: Q1 2026 in Review

Front Row Advisors increased its Arbutus Biopharma (ABUS) stake by 952% in Q1 2026, buying an estimated $437K and bringing the position to 110,500 shares worth $497K. The position accounts for 0.17% of the portfolio, ranked #75.

Front Row Advisors first reported a position in ABUS in Q1 2022 and has held it in 17 quarters since. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2026.

Front Row Advisors held 110,500 shares of Arbutus Biopharma worth $497K as of Q1 2026.
Front Row Advisors bought 100,000 Arbutus Biopharma shares in Q1 2026, an estimated $437K.
Arbutus Biopharma made up 0.17% of Front Row Advisors's portfolio in Q1 2026, its #75 holding.
Front Row Advisors first reported a position in Arbutus Biopharma in Q1 2022 and has held it in 17 quarters since.
167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2026.

Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.